Keyphrases
Acral Lentiginous Melanoma
9%
Advanced or Metastatic
9%
Advanced Solid Tumors
18%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Atomoxetine
9%
Autologous Transplantation
24%
Busulfan
9%
Carboplatin
9%
Confidence Interval
14%
Del17p
7%
Disease Progression
7%
Graft-versus-host Disease (GvHD)
16%
Hazard Ratio
15%
High Risk
14%
High-risk Cytogenetics
11%
High-risk Myeloma
15%
Immune Checkpoint Blockade
13%
Immunohistochemistry
8%
Investigational New Drug
9%
Ipilimumab
11%
Lenalidomide
14%
Lymphoid Malignancies
9%
MD Anderson Cancer Center
9%
Median Overall Survival
10%
Median Progression-free Survival
10%
Melanoma
34%
Melanoma Patients
10%
Merkel Cell Carcinoma
9%
Metastatic Melanoma
13%
Metastatic Tumor
9%
Minimal Residual Disease
10%
Multi-arm
15%
Multiple Myeloma
40%
Multiple Myeloma Patients
31%
Multivariable
11%
Neoadjuvant
18%
Newly Diagnosed multiple Myeloma
24%
Nivolumab
14%
Non-relapse Mortality
7%
Overall Survival
40%
Paclitaxel
9%
Phase Ib Study
15%
Pretransplant
8%
Progression-free Survival
22%
Relatlimab
9%
Response Evaluation Criteria in Solid Tumors (RECIST)
9%
Selinexor
24%
Single Center
22%
Standard Risk
8%
Survival Outcomes
11%
Medicine and Dentistry
Acral Lentiginous Melanoma
12%
Acute Lymphoblastic Leukemia
6%
Acute Myeloid Leukemia
6%
Adverse Event
10%
Allogeneic Stem Cell Transplantation
9%
Allograft
6%
Atomoxetine
9%
Autologous Hematopoietic Stem Cell Transplantation
36%
Autologous Stem Cell Transplantation
13%
Autotransplantation
9%
Cancer
7%
Cell Transplantation
24%
Clinical Trial
6%
Disease Exacerbation
7%
Diseases
20%
Graft Versus Host Reaction
7%
Hazard Ratio
12%
Hematopoietic Cell
25%
Hematopoietic Stem Cell Transplantation
13%
Immune Checkpoint Blockade
13%
Immunoglobulin Producing Cell
7%
Immunohistochemistry
9%
Ipilimumab
8%
Lenalidomide
17%
Lymphoma
10%
Lymphovascular Invasion
7%
Malignant Neoplasm
25%
Melanoma
58%
Melanoma Skin Cancer
18%
Merkel Cell Carcinoma
9%
Metastatic Carcinoma
7%
Metastatic Melanoma
6%
Minimal Residual Disease
7%
Multiple Myeloma
69%
Myelodysplastic Syndrome
6%
Myeloma
6%
Neoplasm
33%
Nevus
7%
Nivolumab
14%
Overall Survival
48%
Prognostic Factor
10%
Progression Free Survival
34%
Recurrence Free Survival
9%
Relatlimab
9%
Selinexor
12%
Sentinel Lymph Node
11%
Solid Malignant Neoplasm
12%
Stem Cell Transplant
12%
Survival Rate
7%
Transplantation
25%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
6%
Adverse Event
20%
Atomoxetine
18%
Attention Deficit Disorder
18%
Bone Marrow Depression
6%
Bortezomib
5%
Brain Metastasis
6%
Busulfan
10%
Carboplatin
9%
Chemotherapy
11%
Clinical Trial
7%
Cutaneous Melanoma
9%
Diseases
20%
Exendin 4
6%
Fludarabine
6%
Graft Versus Host Reaction
7%
Ipilimumab
7%
Lenalidomide
14%
Lymphoma
7%
Malignant Neoplasm
7%
Melanoma
18%
Minimal Residual Disease
5%
Multiple Myeloma
45%
Myelodysplastic Syndrome
10%
Neoplasm
22%
Nivolumab
5%
Non Insulin Dependent Diabetes Mellitus
6%
Olanzapine
6%
Oppositional Defiant Disorder
6%
Overall Survival
42%
Paclitaxel
9%
Pembrolizumab
6%
Placebo
14%
Progression Free Survival
32%
Rapamycin
6%
Recurrence Free Survival
5%
Remission
6%
Selinexor
27%
Solid Malignant Neoplasm
24%
Tolerability
6%
Topotecan
6%